Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2730-y
Published Online: 2015-03-31
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kordes, S.
Klümpen, H. J.
Weterman, M. J.
Schellens, J. H. M.
Richel, D. J.
Wilmink, J. W.
License valid from 2015-03-31